Vident Investment Advisory, LLC Caribou Biosciences, Inc. Transaction History

Vident Investment Advisory, LLC

  • $0
  • Q3 2023

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$4.3 - $7.78 $825 - $1,493
192 Added 1.24%
15,673 $83,000
Q4 2022

Feb 14, 2023
SELL
$5.57 - $11.01 $15,768 - $31,169
-2,831 Reduced 15.46%
15,481 $97,000
Q3 2022

Nov 14, 2022
BUY
$5.34 - $12.79 $9,788 - $23,444
1,833 Added 11.12%
18,312 $193,000
Q2 2022

Aug 15, 2022
SELL
$5.1 - $9.74 $285,023 - $544,339
-55,887 Reduced 77.23%
16,479 $89,000
Q1 2022

May 16, 2022
BUY
$8.42 - $15.32 $101,545 - $184,759
12,060 Added 20.0%
72,366 $664,000
Q4 2021

Feb 14, 2022
BUY
$14.59 - $23.26 $879,864 - $1.4 Million
60,306 New
60,306 $910,000

Others Institutions Holding CRBU

# of Institutions
135
Shares Held
52.6M
Call Options Held
148K
Put Options Held
70.7K
View Full List

About Caribou Biosciences, Inc.

CRBU Quotes by TradingView
  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $123M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Vident Investment Advisory, LLC Portfolio

Follow Vident Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email